JO3796B1 - ميوثينات إنترلوكين 2 لتمدد الخلايا المنظمة t - Google Patents
ميوثينات إنترلوكين 2 لتمدد الخلايا المنظمة tInfo
- Publication number
- JO3796B1 JO3796B1 JOP/2014/0119A JOP20140119A JO3796B1 JO 3796 B1 JO3796 B1 JO 3796B1 JO P20140119 A JOP20140119 A JO P20140119A JO 3796 B1 JO3796 B1 JO 3796B1
- Authority
- JO
- Jordan
- Prior art keywords
- muteins
- regulatory cells
- interleukin
- expansion
- molecules
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 3
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 2
- 102000000588 Interleukin-2 Human genes 0.000 title 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
يتم في هذا الاختراع إعداد جزيئات ميوتينات IL2. وجزيئات اندماج بين Fc وميوتين IL2 والتي يفضل أن تتمدد وتنشط خلايا T التنظيمية ويمكن أن تنتج بكميات كبيرة. ويتم أيضا في هذا الاختراع إعداد جزيئات IgG1 Fc آدمية مغايرة تفتقد بوظيفة مؤثرة منخفضة جدا وثبات مرتفع على الرغم من افتقاد إضافة الجليكوزيل عند N297. وأيضا يتم في هذا الاختراع إعداد ببتيدات ربط والتي تحتوي على وحدات جليكوزيلات عند التعبير عنها في خلايا الثدييات.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361784669P | 2013-03-14 | 2013-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3796B1 true JO3796B1 (ar) | 2021-01-31 |
Family
ID=50680166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2014/0119A JO3796B1 (ar) | 2013-03-14 | 2014-03-16 | ميوثينات إنترلوكين 2 لتمدد الخلايا المنظمة t |
Country Status (40)
Country | Link |
---|---|
US (7) | US9546203B2 (ar) |
EP (2) | EP2970441B1 (ar) |
JP (5) | JP6480409B2 (ar) |
KR (4) | KR20220101009A (ar) |
CN (2) | CN105143253B (ar) |
AP (1) | AP2015008737A0 (ar) |
AR (1) | AR095541A1 (ar) |
AU (2) | AU2014236281B2 (ar) |
BR (1) | BR112015022440B1 (ar) |
CA (3) | CA3149348C (ar) |
CL (2) | CL2015002686A1 (ar) |
CR (2) | CR20200004A (ar) |
CY (2) | CY1121767T1 (ar) |
DK (2) | DK2970423T3 (ar) |
EA (2) | EA032863B1 (ar) |
ES (2) | ES2720225T3 (ar) |
HK (1) | HK1220695A1 (ar) |
HR (2) | HRP20190970T1 (ar) |
HU (2) | HUE043488T2 (ar) |
IL (2) | IL241349B (ar) |
JO (1) | JO3796B1 (ar) |
LT (2) | LT2970423T (ar) |
MA (2) | MA38477B1 (ar) |
ME (2) | ME03482B (ar) |
MX (2) | MX2015012890A (ar) |
MY (2) | MY172991A (ar) |
NZ (1) | NZ751148A (ar) |
PE (1) | PE20151763A1 (ar) |
PH (1) | PH12015502051A1 (ar) |
PL (2) | PL2970441T3 (ar) |
PT (2) | PT2970441T (ar) |
RS (2) | RS58791B1 (ar) |
SG (2) | SG11201507574VA (ar) |
SI (2) | SI2970441T1 (ar) |
TN (1) | TN2015000416A1 (ar) |
TR (2) | TR201910802T4 (ar) |
TW (3) | TWI709572B (ar) |
UA (1) | UA119140C2 (ar) |
UY (1) | UY35454A (ar) |
WO (2) | WO2014153111A2 (ar) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20190202898A9 (en) * | 2012-04-03 | 2019-07-04 | Novelmed Therapeutics, Inc. | AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US9926366B2 (en) * | 2012-10-04 | 2018-03-27 | Novelmed Therapeutics, Inc. | Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies |
US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
WO2014144632A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Human pac1 antibodies |
TR201809571T4 (tr) | 2013-03-15 | 2018-07-23 | Hoffmann La Roche | Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri. |
CA2931114A1 (en) | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
IL289475B2 (en) * | 2014-07-21 | 2023-10-01 | Delinia Inc | Molecules that activate T cells are selectively regulated for the treatment of autoimmune diseases |
SI3180020T1 (sl) | 2014-08-11 | 2019-04-30 | Delinia, Inc. | Modificirane variante IL-2, ki selektivno aktivirajo regulatorne celice T, za zdravljenje avtoimunih bolezni |
AR101875A1 (es) | 2014-09-15 | 2017-01-18 | Amgen Inc | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas |
PL3233192T3 (pl) * | 2014-12-15 | 2021-11-02 | Washington University | Kompozycje i sposoby ukierunkowanego dostarczania cytokin |
TN2017000432A1 (en) * | 2015-04-10 | 2019-04-12 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
AU2016246152A1 (en) * | 2015-04-10 | 2017-11-02 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
WO2017106578A1 (en) | 2015-12-15 | 2017-06-22 | Amgen Inc. | Pacap antibodies and uses thereof |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
US10301391B2 (en) * | 2016-02-03 | 2019-05-28 | Amgen Research (Munich) Gmbh | BCMA and CD3 bispecific T cell engaging antibody constructs |
EA039859B1 (ru) * | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
PL3411404T3 (pl) * | 2016-02-03 | 2023-02-13 | Amgen Research (Munich) Gmbh | Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T |
AU2017213659B2 (en) | 2016-02-05 | 2024-04-18 | Washington University | Compositions and methods for targeted cytokine delivery |
CN107287273B (zh) * | 2016-03-31 | 2021-03-09 | 复旦大学附属妇产科医院 | 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途 |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
CN109071623B (zh) * | 2016-05-04 | 2022-05-27 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
WO2017220704A1 (en) | 2016-06-22 | 2017-12-28 | David Klatzmann | Genetically modified t lymphocytes |
WO2018027025A1 (en) * | 2016-08-03 | 2018-02-08 | Oncomed Pharmaceuticals, Inc. | Cd40-binding agents and uses thereof |
KR101928981B1 (ko) * | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
SG11201903882VA (en) | 2016-11-08 | 2019-05-30 | Delinia Inc | Il-2 variants for the treatment of autoimmune diseases |
US11384336B2 (en) | 2016-12-07 | 2022-07-12 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells |
EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
WO2019112852A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
JP2020521452A (ja) * | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
SG11202003114UA (en) | 2017-10-04 | 2020-05-28 | Amgen Inc | Transthyretin immunoglobulin fusions |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
CA3083941A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Il-2 muteins and uses thereof |
US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
TW201930345A (zh) * | 2017-12-27 | 2019-08-01 | 日商協和醱酵麒麟有限公司 | Il-2改型體 |
CA3087951A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
WO2019158764A1 (en) | 2018-02-16 | 2019-08-22 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
AR115024A1 (es) | 2018-03-28 | 2020-11-18 | Bristol Myers Squibb Co | PROTEÍNAS DE FUSIÓN INTERLEUCINA-2 / RECEPTOR a DE INTERLEUCINA-2 Y MÉTODOS DE USO |
US20210127649A1 (en) | 2018-06-07 | 2021-05-06 | Korea Research Institute Of Bioscience And Biotechnology | Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
KR20210038548A (ko) | 2018-06-22 | 2021-04-07 | 큐진 인크. | 사이토카인-기반 생체활성 약물 및 이의 사용 방법 |
SG11202013138RA (en) | 2018-07-02 | 2021-01-28 | Amgen Inc | Anti-steap1 antigen-binding protein |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
CA3118397A1 (en) * | 2018-11-01 | 2020-05-07 | Shandong Newtime Pharmaceutical Co., Ltd. | Bispecific antibody targeting cd3 and bcma, and uses thereof |
WO2020163782A2 (en) | 2019-02-08 | 2020-08-13 | The Uab Research Foundation | Immunotherapy for the treatment and prevention of inflammatory bowel disease |
SG11202108281UA (en) | 2019-02-15 | 2021-08-30 | Integral Molecular Inc | Claudin 6 antibodies and uses thereof |
US11254736B2 (en) | 2019-02-15 | 2022-02-22 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
US20220193198A1 (en) | 2019-03-29 | 2022-06-23 | Institut Curie | Interleukin-2 Variants with Modified Biological Activity |
CN111944036A (zh) * | 2019-05-14 | 2020-11-17 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
US20220227888A1 (en) | 2019-06-07 | 2022-07-21 | Amgen Inc. | Bispecific binding constructs with selectively cleavable linkers |
WO2021007150A1 (en) | 2019-07-08 | 2021-01-14 | Amgen Inc. | Multispecific transthyretin immunoglobulin fusions |
JP7483857B2 (ja) * | 2019-07-26 | 2024-05-15 | ビステラ, インコーポレイテッド | インターロイキン-2作用物質およびその使用 |
EP4385573A2 (en) * | 2019-08-13 | 2024-06-19 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
TW202124425A (zh) | 2019-09-13 | 2021-07-01 | 日商協和麒麟股份有限公司 | DcR3改型體 |
AU2020389422A1 (en) * | 2019-11-20 | 2022-06-02 | Gi Cell, Inc. | Medium composition for culturing T cells and method for culturing T cells using same |
JP2023505102A (ja) * | 2019-11-29 | 2023-02-08 | エヌケーマックス カンパニー リミテッド | ナチュラルキラー細胞を製造する方法およびその組成物 |
CA3159468A1 (en) | 2019-12-12 | 2021-06-17 | David Klatzmann | Interleukin 2 chimeric constructs |
PE20221506A1 (es) | 2019-12-17 | 2022-10-04 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia |
AU2020407233A1 (en) | 2019-12-20 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Novel IL2 agonists and methods of use thereof |
CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
AU2021252514A1 (en) * | 2020-04-06 | 2022-11-10 | Lung Biotechnology Pbc | Modular synthetic receptors and methods of use |
WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
AU2021283933A1 (en) | 2020-06-04 | 2023-01-05 | Amgen Inc. | Bispecific binding constructs |
WO2021253360A1 (en) * | 2020-06-18 | 2021-12-23 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
CN112048018B (zh) * | 2020-08-31 | 2021-10-08 | 南方医科大学 | 一种嵌合t细胞生长因子及其应用 |
JP2023548311A (ja) | 2020-10-29 | 2023-11-16 | ブリストル-マイヤーズ スクイブ カンパニー | 疾患の治療のための融合タンパク質 |
MX2023006573A (es) | 2020-12-03 | 2023-06-19 | Amgen Inc | Constructos de inmunoglobulina con multiples dominios de union. |
AU2021391924A1 (en) * | 2020-12-04 | 2023-06-22 | The General Hospital Corporation | Methods of using interleukin-2 agents |
TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗il-2r抗體及使用方法 |
BR112023022584A2 (pt) | 2021-05-27 | 2024-01-09 | Sanofi Sa | Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada |
AU2022324624A1 (en) * | 2021-08-06 | 2024-02-08 | Amgen Inc. | Isolation of therapeutic protein |
IL311883A (en) | 2021-10-06 | 2024-06-01 | Assist Publique H?Pitaux De Paris | Interleukin 2 chimeric constructs with targeted specificity for inflammatory tissues |
AU2022364888A1 (en) * | 2021-10-14 | 2024-05-30 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof |
TW202323281A (zh) | 2021-10-14 | 2023-06-16 | 美商泰尼歐生物公司 | 間皮素結合蛋白及其用途 |
WO2023102463A1 (en) * | 2021-12-01 | 2023-06-08 | Visterra, Inc. | Methods of using interleukin-2 agents |
WO2023148397A1 (en) | 2022-02-07 | 2023-08-10 | Vib Vzw | Engineered stabilizing aglycosylated fc-regions |
WO2023164476A2 (en) * | 2022-02-22 | 2023-08-31 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disorders |
WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
US20240166750A1 (en) | 2022-10-25 | 2024-05-23 | Ablynx N.V. | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447A (en) | 1846-04-04 | Car- wheel | ||
US233A (en) | 1837-06-14 | Improvement in plows | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
WO1988007054A1 (en) | 1987-03-18 | 1988-09-22 | Research Corporation Limited | Complement-binding peptide |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
CA2062582C (en) | 1991-03-27 | 1996-03-26 | Tse-Wen Chang | Methods and substances for recruiting therapeutic agents to solid tissues |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
FR2752462B1 (fr) | 1996-08-14 | 1998-10-23 | Essilor Int | Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique |
US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
US6388066B1 (en) | 1998-09-29 | 2002-05-14 | Pioneer Hi-Bred International, Inc. | MAR/SAR elements flanking RSYN7-driven construct |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
ES2311560T3 (es) * | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
US7259010B2 (en) | 2000-12-15 | 2007-08-21 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region of interferon beta |
SG141239A1 (en) | 2001-01-26 | 2008-04-28 | Selexis Sa | Matrix attachment regions and methods for use thereof |
EP2354791A1 (en) | 2001-12-04 | 2011-08-10 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2004251145C1 (en) * | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
US20060234205A1 (en) | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
CA2580141C (en) * | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP2650020B1 (en) * | 2005-05-06 | 2016-08-24 | Providence Health & Services - Oregon | Trimeric OX40-immunoglobulin fusion protein and methods of use |
EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
CN101627054A (zh) * | 2005-07-11 | 2010-01-13 | 马克罗基因公司 | 用人源化抗cd16a抗体治疗自身免疫疾病的方法 |
GB0623539D0 (en) | 2006-11-24 | 2007-01-03 | Avidex Ltd | Polypeptides |
CA2680792A1 (en) | 2007-03-15 | 2008-09-18 | Biogen Idec Ma Inc. | Treatment of autoimmune disorders |
US20090016935A1 (en) | 2007-07-09 | 2009-01-15 | Andrianov Alexander K | Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations |
US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
US8906356B2 (en) * | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
ES2825173T3 (es) | 2009-01-21 | 2021-05-14 | Amgen Inc | Composiciones y métodos de tratamiento de enfermedades inflamatorias y autoinmunitarias |
JP2012515556A (ja) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法 |
JP2013511281A (ja) | 2009-11-23 | 2013-04-04 | アムジェン インコーポレイテッド | 単量体抗体Fc |
MX2012007318A (es) * | 2009-12-22 | 2012-07-20 | Novartis Ag | Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia. |
TWI689314B (zh) | 2010-11-30 | 2020-04-01 | 建南德克公司 | 低親和力血腦障壁受體抗體及其用途 |
HUE055284T2 (hu) * | 2011-02-10 | 2021-11-29 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
EP2686345B1 (en) | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
EP3539982A3 (en) | 2011-12-23 | 2020-01-15 | Pfizer Inc | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
TW201400132A (zh) | 2012-05-21 | 2014-01-01 | Genentech Inc | 改善血腦屏障運送之安全性之方法 |
US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
TR201809571T4 (tr) * | 2013-03-15 | 2018-07-23 | Hoffmann La Roche | Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri. |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2014
- 2014-03-13 US US14/209,914 patent/US9546203B2/en active Active
- 2014-03-13 US US14/209,699 patent/US9580486B2/en active Active
- 2014-03-14 EA EA201591731A patent/EA032863B1/ru not_active IP Right Cessation
- 2014-03-14 SG SG11201507574VA patent/SG11201507574VA/en unknown
- 2014-03-14 PE PE2015002007A patent/PE20151763A1/es active IP Right Grant
- 2014-03-14 AP AP2015008737A patent/AP2015008737A0/xx unknown
- 2014-03-14 KR KR1020227022964A patent/KR20220101009A/ko not_active Application Discontinuation
- 2014-03-14 ES ES14769541T patent/ES2720225T3/es active Active
- 2014-03-14 JP JP2016502936A patent/JP6480409B2/ja active Active
- 2014-03-14 WO PCT/US2014/029111 patent/WO2014153111A2/en active Application Filing
- 2014-03-14 MY MYPI2015002295A patent/MY172991A/en unknown
- 2014-03-14 DK DK14722463.8T patent/DK2970423T3/da active
- 2014-03-14 EP EP14769541.5A patent/EP2970441B1/en active Active
- 2014-03-14 WO PCT/US2014/028913 patent/WO2014153063A1/en active Application Filing
- 2014-03-14 MY MYPI2018002567A patent/MY202248A/en unknown
- 2014-03-14 PT PT14769541T patent/PT2970441T/pt unknown
- 2014-03-14 TW TW108117705A patent/TWI709572B/zh active
- 2014-03-14 TR TR2019/10802T patent/TR201910802T4/tr unknown
- 2014-03-14 CN CN201480014913.7A patent/CN105143253B/zh active Active
- 2014-03-14 CR CR20200004A patent/CR20200004A/es unknown
- 2014-03-14 AR ARP140101154A patent/AR095541A1/es unknown
- 2014-03-14 RS RS20190622A patent/RS58791B1/sr unknown
- 2014-03-14 PL PL14769541T patent/PL2970441T3/pl unknown
- 2014-03-14 MX MX2015012890A patent/MX2015012890A/es active IP Right Grant
- 2014-03-14 KR KR1020157027041A patent/KR102418771B1/ko active IP Right Grant
- 2014-03-14 TW TW109121895A patent/TWI784288B/zh active
- 2014-03-14 KR KR1020157027977A patent/KR102219124B1/ko active IP Right Grant
- 2014-03-14 TW TW103109295A patent/TWI687435B/zh active
- 2014-03-14 AU AU2014236281A patent/AU2014236281B2/en active Active
- 2014-03-14 KR KR1020237037995A patent/KR20230157526A/ko not_active Application Discontinuation
- 2014-03-14 CA CA3149348A patent/CA3149348C/en active Active
- 2014-03-14 BR BR112015022440-7A patent/BR112015022440B1/pt active IP Right Grant
- 2014-03-14 UY UY0001035454A patent/UY35454A/es active IP Right Grant
- 2014-03-14 CA CA2905141A patent/CA2905141A1/en active Pending
- 2014-03-14 PT PT14722463T patent/PT2970423T/pt unknown
- 2014-03-14 LT LTEP14722463.8T patent/LT2970423T/lt unknown
- 2014-03-14 ME MEP-2019-148A patent/ME03482B/me unknown
- 2014-03-14 LT LTEP14769541.5T patent/LT2970441T/lt unknown
- 2014-03-14 CN CN201480027384.4A patent/CN105358570B/zh active Active
- 2014-03-14 DK DK14769541.5T patent/DK2970441T3/da active
- 2014-03-14 MX MX2015012912A patent/MX366854B/es active IP Right Grant
- 2014-03-14 ME MEP-2019-162A patent/ME03437B/me unknown
- 2014-03-14 HU HUE14769541A patent/HUE043488T2/hu unknown
- 2014-03-14 AU AU2014236316A patent/AU2014236316B2/en active Active
- 2014-03-14 TR TR2019/08362T patent/TR201908362T4/tr unknown
- 2014-03-14 SG SG11201507420UA patent/SG11201507420UA/en unknown
- 2014-03-14 ES ES14722463T patent/ES2737598T3/es active Active
- 2014-03-14 PL PL14722463T patent/PL2970423T3/pl unknown
- 2014-03-14 NZ NZ751148A patent/NZ751148A/en unknown
- 2014-03-14 EA EA201591766A patent/EA034326B1/ru not_active IP Right Cessation
- 2014-03-14 MA MA38477A patent/MA38477B1/fr unknown
- 2014-03-14 RS RS20190688A patent/RS58854B1/sr unknown
- 2014-03-14 EP EP14722463.8A patent/EP2970423B1/en active Active
- 2014-03-14 HU HUE14722463 patent/HUE044321T2/hu unknown
- 2014-03-14 JP JP2016502985A patent/JP6450365B2/ja active Active
- 2014-03-14 SI SI201431137T patent/SI2970441T1/sl unknown
- 2014-03-14 SI SI201431252T patent/SI2970423T1/sl unknown
- 2014-03-14 CA CA2906708A patent/CA2906708C/en active Active
- 2014-03-14 UA UAA201509641A patent/UA119140C2/uk unknown
- 2014-03-16 JO JOP/2014/0119A patent/JO3796B1/ar active
-
2015
- 2015-09-09 IL IL241349A patent/IL241349B/en active IP Right Grant
- 2015-09-11 PH PH12015502051A patent/PH12015502051A1/en unknown
- 2015-09-11 TN TN2015000416A patent/TN2015000416A1/en unknown
- 2015-09-14 CL CL2015002686A patent/CL2015002686A1/es unknown
- 2015-09-14 CL CL2015002669A patent/CL2015002669A1/es unknown
- 2015-09-16 IL IL241622A patent/IL241622B/en active IP Right Grant
- 2015-10-09 MA MA49207A patent/MA49207B1/fr unknown
- 2015-10-14 CR CR20150557A patent/CR20150557A/es unknown
-
2016
- 2016-07-20 HK HK16108640.9A patent/HK1220695A1/zh unknown
- 2016-12-06 US US15/371,131 patent/US10093711B2/en active Active
-
2017
- 2017-01-17 US US15/408,281 patent/US9932380B2/en active Active
-
2018
- 2018-02-09 US US15/893,451 patent/US10562950B2/en active Active
- 2018-02-21 US US15/901,705 patent/US10829535B2/en active Active
- 2018-12-06 JP JP2018228769A patent/JP2019058182A/ja active Pending
-
2019
- 2019-05-24 CY CY20191100560T patent/CY1121767T1/el unknown
- 2019-05-28 HR HRP20190970TT patent/HRP20190970T1/hr unknown
- 2019-06-14 HR HRP20191075TT patent/HRP20191075T1/hr unknown
- 2019-07-22 CY CY20191100775T patent/CY1121823T1/el unknown
-
2020
- 2020-10-05 US US17/063,566 patent/US11976102B2/en active Active
- 2020-10-20 JP JP2020175778A patent/JP7227951B2/ja active Active
-
2023
- 2023-02-10 JP JP2023019024A patent/JP2023053148A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502051A1 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
WO2016164937A3 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
SA517390134B1 (ar) | مركبات ميوتين إنترلوكين-2 لتمديد خلايا تائية منظمة | |
MX2023008559A (es) | Proteínas de fusión fc heterodiméricas il15/il15ra. | |
PH12014502767A1 (en) | Interleukin-2 fusion proteins and uses thereof | |
BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
NZ630848A (en) | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | |
SG195306A1 (en) | Purification of biological products by constrained cohydration chromatography | |
GB2513768A (en) | Complexes of cytomegalovirus proteins | |
PH12017501856A1 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
BR112015021993A2 (pt) | composições de cultura celular com antioxidantes e métodos para produção de polipeptídeo | |
WO2012068317A3 (en) | Methods for producing recombinant proteins | |
PH12019501588A1 (en) | Pillow | |
PH12016500708A1 (en) | Recombinant glycoproteins and uses thereof | |
WO2012115903A3 (en) | Yeast strain for the production of proteins with modified o-glycosylation | |
BR112017003074A2 (pt) | Célula isolada, e, métodos de produção de uma proteína recombinante de interesse e de glicosilação de um substrato de proteína de n- glicano. | |
WO2015003811A8 (en) | Methods for producing sialylated therapeutic proteins | |
WO2007146163A3 (en) | Fc-fusion proteins with reduced fc-mediated effector activities |